Sensus Healthcare (NASDAQ:SRTS) Given New $10.00 Price Target at Maxim Group

Sensus Healthcare (NASDAQ:SRTS) had its price target reduced by analysts at Maxim Group from $14.00 to $10.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 128.05% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. Lake Street Capital reduced their price objective on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th.

Sensus Healthcare Trading Down 1.7%

Sensus Healthcare stock traded down $0.08 during midday trading on Monday, hitting $4.39. 44,667 shares of the stock were exchanged, compared to its average volume of 211,371. The stock’s 50-day simple moving average is $4.61 and its 200 day simple moving average is $6.12. Sensus Healthcare has a fifty-two week low of $4.01 and a fifty-two week high of $9.33. The stock has a market capitalization of $72.33 million, a price-to-earnings ratio of 11.00 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.20). The business had revenue of $8.34 million during the quarter, compared to analysts’ expectations of $7.23 million. Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Equities analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Sensus Healthcare

Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new stake in Sensus Healthcare in the 4th quarter worth $27,000. Barclays PLC bought a new position in Sensus Healthcare in the fourth quarter worth approximately $35,000. Larson Financial Group LLC purchased a new position in Sensus Healthcare in the first quarter worth $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Sensus Healthcare during the fourth quarter valued at $47,000. Finally, IFP Advisors Inc acquired a new position in Sensus Healthcare during the fourth quarter valued at $95,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.